Target enzyme mutations are the molecular basis for resistance towards pharmacological inhibition of nicotinamide phosphoribosyltransferase

A Preclinical Study on the Rescue of Normal Tissue by Nicotinic Acid in High-Dose Treatment with APO866, a Specific Nicotinamide Phosphoribosyltransferase Inhibitor

(2010) U. H. Olesen et al.   MOLECULAR CANCER THERAPEUTICS

Nicotinamide phosphoribosyltransferase (NAMPT/PBEF/visfatin) is constitutively released from human hepatocytes

(2009) A. Garten et al.   BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS

The NAD biosynthesis inhibitor APO866 has potent antitumor activity against hematologic malignancies

(2009) A. Nahimana et al.   BLOOD

The Small Molecule GMX1778 Is a Potent Inhibitor of NAD+ Biosynthesis: Strategy for Enhanced Therapy in Nicotinic Acid Phosphoribosyltransferase 1-Deficient Tumors

(2009) M. Watson et al.   MOLECULAR AND CELLULAR BIOLOGY

Crystal structure of Rattus norvegicus Visfatin/PBEF/Nampt in complex with an FK866-based inhibitor

(2009) Gil Bu Kang et al.   MOLECULES AND CELLS

Factors underlying sensitivity of cancers to small-molecule kinase inhibitors

(2009) Pasi A. Jänne et al.   NATURE REVIEWS DRUG DISCOVERY

Anticancer agent CHS-828 inhibits cellular synthesis of NAD

(2008) Uffe Høgh Olesen et al.   BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS

Tumor Cell Metabolism: Cancer's Achilles' Heel

(2008) Guido Kroemer et al.   CANCER CELL

Synthesis and Biological Evaluation of Isosteric Analogues of FK866, an Inhibitor of NAD Salvage

(2008) Ubaldina Galli et al.   ChemMedChem